Problem
Over the past 50 years, petroleum-based polymeric materials have increasingly been used in construction materials, textiles, and computer equipment. To meet fire safety regulations for consumers of these products, flame retardants are incorporated in these inflammable polymers to increase their fire resistance. About 25% of the annual flame retardant production consists of halogenated organics, of which brominated flame retardants (BFRs) are the most important . Although BFRs are beneficial to mankind due to their flame-retarding characteristics, some may also pose a health risk to man and the environment, given their persistent, bioaccumulating, and suspected endocrine-disrupting (ED) potencies.
Characteristics of BFRs
Of all BFRs, tetrabromobisphenol-A (TBBPA), polybrominated diphenyl ethers (PBDEs), and hexabromocyclododecane (HBCD) have the highest consumption figures in the world. TBBPA is produced by bromination of bisphenol-A (Fig. 1) . With an estimated global consumption of 210,000 tons in 1999, TBBPA is the most widely used BFR in the world . PBDEs are characterized by two brominated phenyl rings, connected by an ether bridge (Fig. 1) . As all 10 hydrogen groups of diphenyl ether may be exchanged with bromine during production, theoretically 209 different PBDE congeners can be distinguished. Given the structural similarity between PBDEs and polychlorinated biphenyls (PCBs), PBDEs follow the PCB nomenclature proposed by Ballschmitter and Zell (1980) . PBDEs are typically produced in three different commercial mixtures, each with its own average level of bromination, i.e., penta-PBDE, octa-PBDE, and deca-PBDE mixtures. The commercial penta-PBDE mixture Bromkal 70-5DE consists of 80% of only three congeners, i.e., 35% brominated diphenyl ether (BDE) 47, 38% BDE-99, and 7% BDE-100 ( Fig. 1) (Sjödin et al., 1998) . Octa-PBDE products from different suppliers have different PBDE composition, but in general, hepta-brominated BDE-183 ( Fig. 1) is the major congener (± 44%; Sjödin, 2000) . The deca-PBDE mixture contains > 97% BDE-209 ( Fig. 1) (Marsh, 2003) . In 1999, global market demands of penta-, octa-, and deca-PBDE mixtures were 8500, 3825, and 54,800 tons, respectively . HBCD is the third BFR in production volume with an estimated European market volume of 8950 tons in 1999 (Danish EPA, 1999) . HBCD ( Fig. 1) is produced by bromination of cyclododecatriene, resulting in three different diastereoisomers (alpha, beta, and gamma). Commercial technical HBCD mixtures typically contain 70-90% of the gamma diastereoisomer (Zegers et al., 2005) .
Exposure to BFRs
Several studies have demonstrated that man and wildlife are exposed to BFRs due to their presence in the environment and their bioaccumulating properties (see reviews by Darnerud et al., 2001; Law et al., 2003; Sjödin et al., 2003; Vos et al., 2003) . In short, PBDEs, HBCD, and, to a lesser extent, TBBPA are persistent BFRs with bioaccumulating potencies in the aquatic food chain (e.g., Lindberg et al., 2004; Morris et al., 2004; Zegers et al., 2005) and in man (Darnerud et al., 2001; Weiss et al., 2004) . In general, PBDEs and HBCD are recognized as persistent organic pollutants in the abiotic environment. HBCD and tetra-to hexa-brominated BDE-47, BDE-99, BDE-100, BDE-153, and BDE-154 also dominate BFR composition in biota (including man), but BDE-209 and TBBPA are hardly found in biota, possibly due to low uptake rate or rapid excretion after biotransformation (Boon et al., 2002; Law et al., 2003) .
ED Potency of BFRs
Over the last few years, increasing evidence has become available that some BFRs may have ED potencies (Darnerud et al., 2001; Legler and Brouwer, 2003; Vos et al., 2003) . The structural resemblance between TBBPA and PBDEs to thyroxine (T4), which is the precursor of the active thyroid hormone 3,3#,5-triiodothyronine (T3), may explain the reported interaction of these BFRs with the thyroid axis. In vitro studies demonstrated the T3-like activity of TBBPA and HBCD (Kitamura et al., 2002 (Kitamura et al., , 2005 Yamada-Okabe et al., 2005) . For TBBPA and hydroxylated PBDEs, Meerts et al. (2000) found in vitro competition with T4 for binding to human transthyretin (TTR), the T4-transporting protein in plasma. Decreased plasma T4 levels found in rodents exposed to PBDEs (Zhou et al., 2001 (Zhou et al., , 2002 may be attributed to reduced TTR-mediated transport. Alternative explanations are an induced T4 turnover by induced levels of hepatic uridine phosphoglucuronyl transferase, whereas effects on the thyroid gland or thyroid-stimulating hormone levels are less likely (Zhou et al., 2001 (Zhou et al., , 2002 . Plasma T4 decreases may be involved in the developmental neurotoxic and behavioral effects described for rodents exposed to BFRs (PBDEs and HBCD) and other polyhalogenated aromatic hydrocarbons (Branchi et al., 2003; Eriksson et al., 2002; Porterfield, 2000; Viberg et al., 2003) .
In addition, (anti-)estrogenic properties have been demonstrated in vitro for BFRs. Meerts et al. (2001) found that the estrogen receptor (ER) was activated by lower-brominated PBDEs and inactivated by higher-brominated (hydroxylated) PBDEs. Kester et al. (2002) proposed an alternative (non-ERregulated) estrogenic mechanism by the inhibition of estradiol sulfotransferase enzymes, leading to a decreased sulfation of estradiol (E2) and an associated increased bioavailability of endogenous estrogens. Estrogenic effects of BFRs have hardly been studied in vivo. For TBBPA, estrogenic effects were observed in the mouse uterotropic assay (Kitamura et al., 2005) , whereas no effects were found on quail and chicken embryo development (Berg et al., 2001) .
Recently, Stoker et al. (2005) demonstrated in vivo antiandrogenic properties of PBDEs. In a pubertal exposure study with male Wistar rats exposed to the commercial penta-PBDE mixture DE-71, the authors found delayed puberty and a corresponding suppression of ventral prostate and seminal vesicle growth. DE-71 was also found to be antiandrogenic in an immature rat Hershberger assay. Additional in vitro studies indicated that the DE-71 constituents BDE-47, BDE-99, BDE-100, and BDE-154 inhibited binding of the synthetic androgen R1881 to cytosolic androgen receptor (AR) from the ventral prostate. For BDE-100, this inhibition was demonstrated to be purely competitive. Of the four AR-binding PBDE congeners, BDE-47 and BDE-100 also inhibited dihydrotestosteroneinduced, human AR-regulated transcriptional activation in a luciferase reporter gene assay (Stoker et al., 2005) .
Finally, some PBDE congeners can activate or inactivate the arylhydrocarbon receptor (AhR, or dioxin receptor [DR]; Behnisch et al., 2003; Meerts et al., 1998) , which is directly involved in the expression of cytochrome P450-1A. In vivo, increased hepatic ethoxyresorufin O-deethylase (EROD) activity has been demonstrated in rats exposed to PBDEs (e.g., Zhou et al., 2001 Zhou et al., , 2002 . With respect to endocrine disruption, induced or inhibited DR-regulated enzyme activities may directly or indirectly affect critical pathways in vitamin A metabolism (Zile, 1992) or steroidogenesis (Fukazawa et al., 2004) .
Aim of This Study
Despite indications for bioaccumulating and the ED properties of BFRs, a human and ecological risk assessment for these compounds has been hampered by the lack of a systematic identification and toxicological characterization of the most potent and environmentally relevant BFRs (Vos et al., 2003) . The goal of the current study was to perform a systematic in vitro screening of the potential ED potencies of BFRs, as part of a hazard identification approach within the EU-funded research program FIRE (RIVM, 2003) . For the in vitro screening, a test set of 27 individual BFRs were selected, consisting of TBBPA, 19 PBDEs, HBCD (technical mixture [TM] and the alpha, beta, and gamma diastereoisomers), 2,4,6-tribromophenol (246-TBP), and ortho-hydroxylated brominated diphenyl ether 47 (6OH-BDE-47). The test set further included tetrabromobisphenol-A-bis(2,3)dibromopropyl ether (TBBPA-DBPE), which is used as a flame-retarding additive for plastics. The subset of PBDEs contained environmentally relevant and also less environmentally relevant congeners. The latter were selected to cover a broad variation in chemical characteristics in the test set, to allow the establishment of quantitative structure-activity relationships (QSARs) that will be described elsewhere (Harju et al., in press ). The test set was completed by commercial penta-and octa-PBDE mixtures. All compounds were tested for their potency to interfere via thyroidal, estrogenic, and AhR-mediated pathways. In addition, the potency to interfere with androgenic and progestagenic pathways was tested for the first time for BFRs.
Altogether, all compounds were tested in seven different bioassays for 12 endocrine-related modes of action (Table 1) . Results from the in vitro screening were used for (1) identification of relevant endocrine-related modes of action that may be affected by BFRs in man and wildlife and (2) classification of BFRs with similar ED profiles. 3, 3#, 4, 4#, 5, 6] , 2#3, 3#, 4, 4#, 5, 5#, 6] , and 2#3, 3#, 4, 4#, 5, 5#, 6 ,6#] and 6OH-BDE-47 (> 99%; cleaned up on charcoal column to remove possible impurities of brominated dibenzofurans and dioxins) were obtained from Stockholm University through Dr Göran Marsh and Dr Å ke Bergman. 2#, 6] , 4, 5] , 4#, 5] , 3#, 4, 5#] , 5, 5#], 2#, 3, 4, 5, 5#, 6 ] (> 98%) were bought from AccuStandard (New Haven CT). Penta-PBDE mixture DE-71 and octa-PBDE mixture Octa LM were obtained from Great Lakes CALUX bioassays. For all test compounds, the potency to interact as an agonist or antagonist with the AhR, the ER, the AR, and the progesterone receptor (PR) was determined in the DR-, ER-, AR-, and PR-CALUX bioassays, respectively (Legler et al., 1999; Murk et al., 1996; Schreurs et al., 2005) . All four CALUX bioassays (chemically activated luciferase gene expression; BioDetection Systems BV [BDS] , Amsterdam, The Netherlands) make use of reporter cell lines carrying a luciferase gene under the transcriptional control of response elements for activated receptors. The four CALUX bioassays were performed according to protocols from BDS. Methodological differences among the four CALUX bioassays are indicated in Table 2 . In short, cells were plated in 96-well plates with the medium supplemented with fetal calf serum (FCS; Table 2 ). After a given period of time (see Table 2 ), the medium was refreshed with exposure medium containing the BFR to be tested (maximum concentration 10 or 12.5lM), in the absence or in the presence of a reference agonist. After 24 h of incubation, the medium was removed; cells were lysed in 30 ll of Triton-lysis buffer and measured for luciferase activity using a luminometer.
MATERIALS AND METHODS
Estradiol sulfotransferase assay. The estradiol sulfotransferase (E2SULT)-inhibiting potency of BFRs was determined according to Kester et al. (2000) with minor modifications. In short, the effect of BFRs on the formation of E2 sulfate was determined after incubation of tritium-labeled estradiol ( 3 H-E2), sulfotransferase, and the cofactor 3#-phosphoadenosine-5#-phosphosulfate (PAPS). Recombinant human sulfotransferase 1E1 (SULT1E1) expressed in a V79-1E1 Chinese hamster cell line (Czich et al., 1994) was kindly provided by Prof. Dr H. Glatt (German Institute of Human Nutrition). SULT1E1 was incubated (37°C; 30 min; 2 lg cytosolic protein/ ml) with 1nM 3 H-E2 (2, 4, 6, 7, 16, H-estradiol; Amersham Biosciences [Buckinghamshire, UK]) and 50lM PAPS (Sigma-Aldrich) in 0.2 ml of 0.1M sodium phosphate (pH 7.2), 2mM EDTA, and 1mM dithiothreitol in the presence or absence (control) of the test compound (maximum concentration 10lM) or pentachlorophenol (PCP), used as a reference material (Kester et al., 2000) . Maximum concentration of the test compounds during incubation was 10lM, and all incubations contained 1% DMSO. Blank incubations received no PAPS. The reaction was stopped by adding 800 ll of ice-cold water. Unreacted 3 H-E2 was removed by extraction of the incubation mixture with 2 ml of dichloromethane. The amount of water-soluble 3 H-E2 sulfate was quantified by counting 0.5 ml of the water phase in a beta counter (LKB Wallack 1219 Rackbeta).
TTR-binding assay. The capacity of BFRs to compete with T4 for binding to TTR was investigated according to Lans et al. (1993) with modifications. Human TTR (prealbumin from human plasma, Sigma-Aldrich; 30nM) was incubated overnight at 4°C in a final volume of 200 ll 0.1M Tris-HCl buffer (pH 8.0; 0.1M NaCl, 0.1mM EDTA) with a mixture of T-Screen. BFR potency to act as a thyroid hormone receptor (TR) agonist or antagonist was tested in the T-Screen (Gutleb et al., 2005) , a functional assay Cytotoxicity. To ensure that reduced activities in the various bioassays were caused by true antagonistic responses and not by cytotoxicity, viability was measured in DR-CALUX and ER-CALUX cells exposed to 10 or 12.5lM BFR, which was the maximum concentration tested in the CALUX assays ( Table 2 ). As in the T-Screen, cell viability was measured as the metabolic capacity to reduce blue resazurin into pink resorufin (O'Brien et al., 2000) . CALUX cells were plated as in the original CALUX assay. CALUX cells were exposed for 24 h to exposure medium (cell-specific medium containing BFR and 40lM resazurin), and metabolic capacity was determined spectrophotometrically (SpectraMAX 340 PC) as a decrease of the blue-colored resazurin (k ¼ 600 nm) in the assay medium.
Data analysis. For all bioassays, dose-response curves were determined for those compounds showing effects > 20% of control level in earlier rangefinding experiments. EC 50 or IC 50 values were calculated for those compounds for which a full dose-response curve could be constructed. For compounds yielding responses between 10 and 50% of control level within the range of test concentrations, EC 50 or IC 50 values were either extrapolated from the doseresponse curve (in case the extrapolated value was reasonably close to the highest test concentration) or set at a minimum value (see Tables 4-8) . In most bioassays, dose-response curves reached maximum responses (sometimes after extrapolation) comparable to the reference compound. For only a few DRagonistic and E2SULT-inhibiting BFRs, maximum responses were lower than for reference compounds. In these cases (indicated by footnotes in Tables 4 and  7 , respectively), EC 50 or IC 50 values were calculated as the concentration at the point of inflection in the compound-specific dose-response curve and not as the concentration corresponding with 50% of the maximum response induced by the reference material. In vitro, ED potencies of all BFRs were classified according to the criteria listed in Table 3 . Classification was based on EC 50 or IC 50 values, except for T-Screen results, which did not allow EC 50 estimation due to cytotoxicity. For each BFR, a compound-specific toxicity profile was constructed including a set of 12 classified ED activities determined in vitro.
Toxicity profiles of all 27 BFRs were analyzed for common features using two different pattern recognition methods: hierarchical cluster analysis and principal component analysis (PCA). In both methods, the BFR-specific toxicity profile is considered as a set of coordinates that define the position of the BFR in a 12-dimensional space. Two different pattern recognition methods were chosen to improve interpretation and to verify results from one method with those from the other method.
Hierarchical cluster analysis (e.g., Aldender and Blashfield, 1984 ) is a pattern recognition method that is solely based on the calculated distances between the 27 BFRs within this 12-dimensional space. In the first stage, the two BFRs with lowest distance are grouped together into a cluster. Next, an average location for this cluster is calculated in the 12-dimensional space. In the second stage, distances between the remaining 25 BFRs and the new cluster are calculated and cases with lowest distance merged again. This can be a third and a fourth BFR that merge into a second cluster, but also a third BFR that is added to the first cluster. This procedure is repeated, adding BFRs to existing clusters, creating new clusters, or combining clusters until only one cluster is left. Results from a hierarchical cluster analysis may be presented in a so-called dendrogram (see Fig. 3 ), a diagram that illustrates the fusions made at successive stages of analysis and indicates the relative distance between the different BFRs and clusters in the 12-dimensional space. Hierarchical cluster analysis was performed in SPSS (version 10.0 for Windows) based on squared Euclidean distances between class values using the between-group linkage method.
In PCA (e.g., Jackson, 1991) , the 27 BFRs located in the 12-dimensional space are projected down to a lower-dimensional hyperspace. In Figure 4 , a score plot is shown where two latent explanatory variables (principal components or PCs) are used as x-axis and y-axis. These two orthogonal vectors are calculated in such a way that PC1 explains the largest part of the total variance, PC2 the largest part of the remaining variance, etc. The score plot yields an overview of the major patterns in the data set, and BFRs found closely together have a similar toxicity profile. The distance of a particular BFR to the origin indicates its deviation from the toxicity profile of the ''average BFR.'' Similarly, the significance of the original 12 bioassay responses can be illustrated in a so-called loading plot, where highly significant ED potencies have a larger distance to the origin than less-significant potencies. By superimposing the loading plot on the score plot (as done in Fig. 4) , correlations between BFRs and bioassay responses can be visualized: BFRs and bioassay responses located closely together are positively correlated, whereas BFRs and bioassay responses with opposite positions are negatively correlated. The PCA calculations were performed in Simca-Pþ 10.0 (Umetrics Inc, Umeå, Sweden), using a cutoff in eigenvalue of 2 to define the number of significant components.
RESULTS

CALUX Bioassays
Of the nine DR-agonistic PBDEs, only four (BDE-38, BDE-153, BDE-190 and 6OH-BDE-47) were able to induce a full (Fig. 2) . Based on EC 50 values, BDE-38 was the most potent compound, with a DR-agonistic potency of about 56,000 times less than that of TCDD (Table 4) . DR-antagonistic activity was found for lower-brominated PBDEs (up to hexabrominated BDE-169) and to some extent for HBCD (Table 4) . BDE-47 was the most potent DR antagonist tested (IC 50 ¼ 2.7lM), with activities similar to the reference antagonist PCB-128 ( Fig. 2 ; Table 4 ).
No agonistic AR and PR activity could be demonstrated for any of the BFRs tested. However, for 22 out of the 27 BFRs, antiandrogenic and-to a lesser extent-antiprogestagenic activities were found (Table 5) . Only BDE-169, BDE-206, BDE-209, TBBPA, and TBBPA-DBPE did not show any ARand PR-antagonistic activity. Highest AR antagonism was found for BDE-19 and BDE-100 with IC 50 values of 0.060 and 0.097lM, respectively (Table 5 ; Fig. 2 ). Together with BDE-47 and BDE-49, these BFRs were more potent than the antiandrogenic drug flutamide (IC 50 ¼ 1.3lM) that was used as a reference AR-antagonistic compound . PR-antagonistic activity was also highest for BDE-19 (IC 50 ¼ 0.8lM). In addition, IC 50 values of 5lM were found for HBCD (TM and gamma diastereoisomer), BDE-100, (Table 5 ). All PR-antagonistic BFRs were more than three orders of magnitude less potent than the pregnancyterminating and breast cancer drug RU-486 that was used as an 
1.3 ± 0.4 6.9 ± 0.8 3 10 antiprogestagenic reference compound (Mahajan and London, 1997) .
ER-agonistic (i.e., estrogenic) responses were only found for low-brominated diphenyl ethers (up to hexa-brominated BDE-155), with EC 50 values > 2lM (Table 6 ). Estrogenic potency of BFRs was six orders of magnitude lower than for the natural ligand E2, with highest potency for BDE-19 (EC 50 ¼ 2.4lM; Fig. 2 ) for which a molar E2 equivalency factor (E2 EF) of 1.26 3 10 -6 was found (Table 6 ). ER-antagonistic (i.e., antiestrogenic) responses were found for tetra-brominated BDE-79, all hepta-brominated PBDEs in the test set (i.e., , HBCD, and the phenolic compounds 6OH-BDE-47 and 246-TBP (but not TBBPA). The most potent test compound was 6OH-BDE-47 (IC 50 ¼ 0.5lM; Fig. 2) , which was 3000 times less potent than the antiestrogenic drug ICI 182.780 (Table 6 ) that was used a reference compound (Legler et al., 1999) .
E2SULT Assay
TBBPA was the most potent inhibitor of E2 sulfation (IC 50 ¼ 0.016lM), being almost 13 times more potent than the wellknown inhibitor PCP (Table 7 ; Fig. 2 ). 246-TBP and to a lesser extent 6OH-BDE-47 were also potent E2SULT inhibitors, indicating that the E2SULT-inhibiting potency is supported by the presence of a hydroxylated aromatic group. Although full dose-response curves were obtained within the range of test concentrations, maximum E2SULT-inhibiting potencies of only 60, 50, and 40% were found for the lower-brominated BDE-19, BDE-47, and BDE-49, respectively (see BDE-47 in 
Thyroid-Related Assays
246-TBP and TBBPA were also very potent T4 competitors in the TTR-binding assay (IC 50 < 0.1lM) with a 10.2 and 1.6 times higher TTR-binding potency than the natural ligand T4 ( Fig. 2; Table 7 ). While 6OH-BDE-47 is the third most potent inhibitor in order and nonhydroxylated PBDEs and HBCD have much lower T4-competing potency, a hydroxylated aromatic group seems to be required for TTR-binding capacity.
In the absence of T3, the T-Screen-agonistic activity was found for HBCD alpha at 1lM (up to 21% of the maximum T3-induced proliferation; Fig. 2 ) and to a lesser extent for BDE-127 and BDE-185 (Table 8) . When tested in the presence of 0.25nM T3, however, 13 BFRs were able to increase the T3 response from 50 to 94% of the maximum T3-induced response. This potentiating effect was most pronounced for BDE-49, BDE-100, and HBCD alpha and gamma diastereoisomers (Fig. 2, Table 8 ). In contrast, BDE-206 caused a significant decrease in T3-induced cell proliferation at concentrations exceeding 0.1lM (Fig. 2) .
Cytotoxicity
For all BFRs, microscopic observations revealed visible cytotoxicity in GH3 cells (T-Screen) at concentrations 1lM, whereas no cytotoxicity was seen in any of the CALUX cells at maximum test concentrations. Since antagonistic responses in cell-based bioassays could be competed out in most cases by excess of the reference agonist (100 3 EC 50 ; data not shown), inhibition could be attributed to true antagonism (i.e., competition for the receptor-binding sites) and not to cytotoxicity. Antagonistic responses of 6OH-BDE-47, 246-TBP, and HBCD Tables 5  and 6 ). In these few cases, cytotoxicity may have contributed to the antagonistic response, although microscopic cell damage was not observed. Also, additional cell viability assays with resazurin did not indicate cytotoxicity for these ''suspected'' BFRs in DR-and ER-CALUX cells.
Toxicity Profiling
Cytotoxicity in the T-Screen at BFR-concentrations > 1lM hampered the calculation of full dose-response curves with EC 50 values for T3 potentiation. To enable the inclusion of TScreen results in a toxicity-profiling analysis together with those from the other bioassays for which EC 50 or IC 50 were available, all bioassay results were classified into dimensionless classes according to predefined criteria (Table 3) . As is the case with EC 50 or IC 50 values, these classes only reflect relative differences in ED potency of BFRs within one single bioassay, but not among different bioassays.
After classification, compound-specific toxicity profiles were established, which were further arranged into five different clusters of BFRs using hierarchical cluster analysis (Fig. 3) . Cluster I consists of BFRs with moderate to very high TTR-binding affinity and high to very high E2SULT-inhibiting potency. This category includes the phenolic compounds 246-TBP and TBBPA and the TBBPA derivative TBBPA-DBPE. Cluster II consists of BDE-19, BDE-49, BDE-100, and BDE-155 with moderate to very high antiandrogenic activity, moderate to high antiprogestagenic and T3-potentiating activities, and moderate estrogenic activity. Cluster III consists of HBCD (TM and the three individual diastereoisomers) and BDE-28 with moderate to high T3-potentiating activity and low to moderate antiandrogenic and antiprogestagenic activity in combination with low to moderate DR-antagonistic activity. Cluster IV consists of tri-to hepta-brominated PBDEs and 6OH-BDE-47 with moderate to high DR-agonistic activity, in combination with low to moderate antiandrogenic and antiprogestagenic activities. This cluster includes a subset (IV.2) of 6OH-BDE-47, BDE-183, and BDE-190 with a very similar profile of moderate to high ED potencies for 6 of the 12 endpoints tested (AR, PR, and ERantagonism, DR agonism, E2SULT inhibition, and TTR-binding affinity). Cluster V seems to consist of ''rest'' BFRs and can be divided into BFRs without (V.1) and with (V.2) AR-and PR-antagonistic activities. BDE-47 seems to be an outlier for this cluster of BFRs, as can be seen from its relatively long distance from the other BFRs in cluster V. PCA was performed on the classified toxicity profiles based on the 10 ED endpoints for which a response was found for any of the 27 BFRs tested (i.e., omitting the negative AR-and PRagonistic results found for all tested BFRs). Results from the PCA are shown in Figure 4 as a two-dimensional score plot with superimposed loading plot (see ''Materials and Methods'' section). To allow a direct comparison between results from both pattern recognition methods, BFR markers in the PCA plot have the same color as their corresponding cluster distinguished in the hierarchical cluster analysis in Figure 3 (first column). The first PC, PC1, explained 29% of the variation in the data set. PC1 is clearly associated with differences in TTR-binding and E2SULT-inhibiting potencies (cluster I) on the one hand (left side of Fig. 4) and AR-and PRantagonistic, ER-agonistic, and T-Screen-potentiating potencies (cluster II) on the other hand (right side of Fig. 4) . The second PC, PC2, explained 21% of the variation and seems to be associated with differences in DR-agonistic potencies (cluster IV; top side of Fig. 4) and DR-antagonistic potencies on the other side (clusters III and V; bottom side of Fig. 4) . The third PC, PC3, had a low significance (eigenvalue < 2) and explained only 16% of the variation. PC3 is not shown in the two-dimensional biplot of Figure 4 , but the marker triangles for BFRs and bioassay endpoints point in the direction by which they were oriented in the third dimension. As can be seen from Figure 4 , PC3 roughly distinguishes between BFRs with specific high potencies (clusters I and II) or broad potencies (cluster IV.2) on the one hand (markers pointing up in Fig. 4 ) and all remaining BFRs on the other hand (markers pointing down). PC3 especially distinguishes among BFRs located in the left side of Figure 4 , separating potent TTR-binding and E2SULT-inhibiting BFRs from the inactive BDE-169 and BDE-209 and the T3-antagonistic BDE-206.
DISCUSSION
In Vitro ED Potency of BFRs
The in vitro screening demonstrated that ED mechanisms of action that were only described for a few BFRs so far, are shared by a wider set of BFRs than ever tested before. For instance, AR-antagonistic potencies recently demonstrated for penta-PBDE mixture DE-71 and BDE-100 Stoker et al., 2005) were found for 18 out of the 27 BFRs in the test set (IC 50 < 15lM; Table 4 ). In addition, ARantagonistic responses were among the highest of all bioassay responses determined in the present study, with maximum potencies for BDE-19 and BDE-100 being higher than for flutamide, an antiandrogenic drug used in prostate cancer treatment. Given the presence of BDE-100 in the penta-PBDE mixture, this relatively high AR-antagonistic potency seems to be especially relevant. Using a QSAR model based on the AR-CALUX results of the present study, Harju et al. (in press ) predicted AR-antagonistic activity (IC 50 ¼ 0.1-3.1lM) for the nontested penta-PBDE mixture constituents BDE-17, BDE-66, BDE-85, and BDE-154. In general, the QSAR model predicted high AR-antagonistic potency for low-brominated PBDEs with ortho or ortho-para substitution. For TBBPA, the present study TBBPA-DBPE --a n 2; -: no response. b Determined at 0.5lM due to cytotoxicity at 1lM. c n ¼ 1.
FIVE DIFFERENT TOXICITY PROFILES FOR BFRS
167 confirmed a lack of AR-(ant)agonistic potency recently reported by Kitamura et al. (2005) . In addition, PR-antagonistic potencies of BFRs have been demonstrated for the first time. In general, PR-antagonistic potencies were more than three orders of magnitude lower than found for the abortifacient RU-486, of which the mechanism of action is based on blocking PR. Especially for the lowerbrominated diphenyl ethers, a significant correlation was found between PR-antagonistic potencies and AR-antagonistic potencies (Table 5) , although the first was generally lower than the latter. The PR-antagonistic activities of HBCD and again penta-BDE-100 seem to be especially of interest, given the abundant presence of these BFRs in the environment. The low PR-antagonistic activity of the penta-PBDE mixture (Table 5) may partly be attributed to not only BDE-100 but also to BDE-66, BDE-85, BDE-138, and BDE-154, for which Harju et al. (in press) predicted IC 50 values of 9-20lM using a QSAR model based on the PR-CALUX results presented here. In general, the QSAR model predicted highest PR-antagonistic potency for PBDEs with a tri-or tetra-ortho substitution.
In contrast to the DR and ER responses, AR and PR were not activated agonistically by any of the BFRs tested. A lack of the AR-activating potency seems to be a general feature for environmental AR ligands (e.g., Schreurs et al., 2005) , possibly because activation of the AR is a more complex mechanism depending on C-and N-terminus interactions and specific coactivators . Similar complex activation processes may be involved in PR activation.
The T-Screen results confirmed effects of the high-production BFRs TBBPA and HBCD on in vitro thyroid hormone-signaling studies described before (Kitamura et al., 2002 (Kitamura et al., , 2005 Yamada-Okabe et al., 2005) . In addition, the current study demonstrated such potencies for another eight PBDE congeners, of which BDE-100 and BDE-49 are the most environmentally relevant. Interestingly, most BFRs exhibited T-Screen activities only when tested in the presence of T3 (Table 8) . For HBCD, similar results were obtained before Yamada-Okabe et al., 2005) . For TBBPA, however, Kitamura et al. (2002 Kitamura et al. ( , 2005 demonstrated the T3-like activity of TBBPA in GH3 cells in both the absence and the presence of T3. The explanation for these contradictory results could be the use of serum-free medium in our study, excluding the chance of any remaining T3 in the exposure mixture. The use of serum-free medium may also (partially) explain the   FIG. 3 . Hierarchical clustering analysis of the classified in vitro toxicity profiles of 27 BFRs. The relative difference in toxicity profiles between two compounds is indicated by the horizontal distances to be bridged when moving from one compound to the other according to the branches of the dendrogram tree shown at the right side. Numbers indicate the relative potencies for the different ED modes of action according to the criteria in Table 3 . Asterisks indicate cases with BFR dose-response curves that did not reach the maximum response of reference compounds TCDD (DR ago) or PCP (E2SULT). In these cases, EC 50 and IC 50 values were calculated as the point of inflection in the compound-specific dose-response curve; ago, agonism; anta, antagonism; pot, potentiation; other abbreviations as in Figure 2 . differences in cytotoxicity of TBBPA, which starts at concentrations > 1lM in our study but did not occur until 100lM in the study of Kitamura et al. (2005) .
In a previous study on the T4-TTR-binding competition by BFRs, Meerts et al. (2001) found no TTR binding for 17 different PBDE congeners at maximum concentrations of 0.25lM (including BDE-47, BDE-99, BDE-100, . In the present study, TTR binding of PBDEs was found at much higher concentrations indeed. As in the present study, Meerts et al. (2001) also found higher TTRbinding potencies for TBBPA and 246-TBP than for the natural ligand T4 (Table 7) . These results confirm the proposed prerequisite for TTR-binding PCBs, i.e., hydroxylation at the para position with one, but preferably two, adjacent halogen substituent (Lans et al., 1993) . The structure of 6OH-BDE-47 does not fully comply with this optimum prerequisite. This may explain why the TTR-binding potency of this PBDE metabolite is higher than for nonhydroxylated PBDEs but lower than for TBBPA and 246-TBP.
Inhibition of E2SULT is another endocrine-related endpoint that so far was demonstrated for a limited number of BFRs, i.e., 246-TBP, TBBPA, and some OH-PBDE congeners (Kester et al., 2000 (Kester et al., , 2002 . As for TTR binding, Kester et al. (2000) found highest E2SULT-inhibiting potency for coplanar para-hydroxylated organohalogens with halogen substitution on the phenolic ring, preferably at both places adjacent to the hydroxy group.
Indeed, 246-TBP and TBBPA had high to very high E2SULT-inhibiting potencies (Kester et al., 2002;  Table 7) , whereas 6OH-BDE-47 (Table 7) had moderate to high inhibiting potencies. Moreover, the E2SULT-inhibiting potency was found for another four PBDEs (Table 7) , although the relatively high E2SULT-inhibiting potency of the most common congener BDE-47 (Fig. 3) is probably overestimated because it is based on an IC 50 value of 0.8lM (i.e., point of inflection in the dose-response curve of Fig. 2 ). Compared to the reference compound PCP, however, only 40% inhibition was reached at the maximum BDE-47 concentration of 10lM (Fig. 2) .
The ER-agonistic potencies found for the environmentally relevant PBDE congeners BDE-28, BDE-47, and BDE-100 (Table 6 ) confirm ER-CALUX results reported by Meerts et al. (2001) . Compared to this latter study, estrogenic activity of BDE-99 (only 2% of the maximum induction by 30pM E2) was probably too low to be confirmed in the present study, whereas antiestrogenic potency for BDE-153 and BDE-190 could only be confirmed for the latter congener. The additional ERagonistic responses found in the present study for , and the octa-PBDE mixture (Table 6 ) confirm the general observation by Meerts et al. (2001) that estrogenic activity is associated with lower-brominated PBDEs and antiestrogenic activity with higher-brominated PBDEs. For estrogenic PBDEs, Meerts et al. (2001) described common structural features as ''two ortho (2,6)-bromine atoms on one phenyl ring, at least one para-bromine (preferably on the same phenyl ring as the ortho bromines), and nonbrominated orthometa-or meta-carbons on the other phenyl ring.'' Of the six Figure 3 ; for each BFR and bioassay, the triangle points at the direction of ordination in the third dimension (PC3), i.e., above (D) or below (=) the two-dimensional plane described by PC1 and PC2; ago, agonism; anta, antagonism; pot, potentiation; other abbreviations as in Figure 2 .
PBDEs with moderate ER-agonistic activity (Table 6) , only BDE-100 and BDE-155 comply with this structure-activity relationship. The current data suggest that ER-agonistic activity of PBDEs concurs with a [2,2#6] or a [2,2#,4] substitution and no bromine substitutions adjacent to each other. Still, both closely related descriptions do not cover the relatively potent 3,4,5-substituted BDE-38. With respect to non-PBDEs, a weak agonistic (EC 50 ¼ 19lM) as well as an antagonistic (IC 50 10lM) activity was found for TBBPA in a luciferase reporter gene assay with human mammary cancer MCF-7 cells (Kitamura et al., 2005) , but not in the ER-CALUX assay (Table 6 ; Meerts et al., 2001) . The high antiestrogenic activity for 6OH-BDE-47 and 246-TBP (Table 6 ) should be interpreted with care. Since this ER-antagonistic activity could not be competed out with 1000pM E2 (¼ 250 3 EC 50 ), it is possible that these compounds suppress the E2-induced response by cytotoxicity, although additional cell viability assays with resazurin did not indicate cytotoxicity for 6OH-BDE-47 or 246-TBP in ER-CALUX cells.
The present study confirms results from earlier DR-CALUX bioassay studies, indicating that PBDEs may act as weak DR agonists. For BDE-28, BDE-47, BDE-99, BDE-100, 246-TBP, and HBCD (alpha, beta, and gamma diastereoisomers), the low to absent DR-agonistic potency (Table 4) confirmed earlier DR-CALUX results (Behnisch et al., 2003; Meerts et al., 1998; Murk et al., 1996) . Maximum DR-agonistic potencies of more than four orders of magnitude lower than TCDD were found for (Table 4) , of which the latter two are relevant from an environmental point of view. The DRagonistic potency of BDE-190 was similar to that reported by Meerts et al. (1998) but higher than found by Behnisch et al. (2003) . BDE-153 and BDE-183 showed a higher DR-agonistic potency compared to all earlier studies (Behnisch et al., 2003; Meerts et al., 1998; Murk et al., 1996) . The relatively high DRagonistic potencies of [2,2#]-substituted BDE-153 and BDE-183 are remarkable results, given the lack of DR-agonistic potency reported for [2,2#]-substituted PCBs including PCB-153 ( Van der Plas et al., 1998) . Possibly, BDE-153 fits better in the DR-binding pocket than PCB-153 due to the presence of an ether bridge between the two phenyl rings, which is absent in PCB-153.
DR antagonism of BDE-28, BDE-47, BDE-99, and BDE-100 confirmed DR-CALUX results by Meerts et al. (1998) , but potencies were higher in the present study. In both studies, the environmentally predominant BDE-47 was the most potent congener. In addition, DR-antagonistic responses were found for four other PBDE congeners, the penta-and the octa-PBDE mixtures, and HBCD (Table 4) , although potencies were moderate to low.
Except for the commercially obtained PBDEs 19, 38, 39, 79, 127 , and 185, all other PBDE congeners and mixtures were cleaned on a charcoal column before preparing stock solutions in DMSO. Cleanup was performed to remove low levels of DR-agonistic polybrominated dibenzofurans (PBDFs) and dibenzo-p-dioxins (PBDDs) that may be formed during PBDE synthesis and may act as potent DR agonists. This removal may explain why the present study could not confirm the DRagonistic potency reported for noncleaned BDE-209 (Behnisch et al., 2003) . Although the contribution of PBDF and PBDD contamination to the DR-agonistic response of BDE-38 and BDE-79 (Table 4) is highly unlikely (Accu Standard, personal communication), it cannot be completely excluded (Å ke Bergman, personal communication). Therefore, DR-agonistic responses of these two PBDEs should be handled with care. Non-PBDE compounds were not cleaned before preparing stock solutions in DMSO because PBDF and PBDD formation is not to be expected during the synthesis of these compounds. Nevertheless, the TMs of HBCD and TBBPA-DBPE may still be contaminated with other intermediate compounds. In particular, a possible contamination of TBBPA-DBPE with TBBPA could explain the (very) high potency of TBBPA-DBPE in the TTR and E2SULT assays.
Toxicity Profiling
Hierarchical cluster analysis and PCA were used to present the complex data set (i.e., toxic potencies of 27 BFRs towards 12 endocrine-related modes of action) in a single diagram. Both the dendrogram in Figure 3 and the PCA plot in Figure 4 can be used to identify the most potent BFRs and their most important modes of action. By pattern recognition, both methods provide new information about similarity and dissimilarity in toxicity profiles of the individual BFRs, which can be indicative of structural features or other chemical characteristics that are required for a given mode of action. In addition, this new information can be used to design further (in vivo) studies and to select indicator BFRs representing different toxicity profiles that should be tested in such studies (see next paragraph).
Cluster II (Fig. 3) for instance consists of tri-to hexabrominated BDE-19, BDE-49, BDE-100, and BDE-155 with a di-ortho [2,2#] substitution and no bromine substitutions adjacent to each other on a single aromatic ring. BDE-47 is the only other BFR in the test set that complies with this description. Although its toxicity profile is very similar to that of BDE-19, BDE-49, BDE-100, and BDE-155 (four out of five endpoints overlap), BDE-47 is not clustered accordingly in cluster II, probably because of its lower potencies. The similarity in profile but dissimilarity in potencies is illustrated in the PCA plot (Fig. 4) , where BDE-47 is located in between clusters V.1 (inactive BFRs) and II, indicating that BDE-47 was erroneously clustered with the rather inactive rest BFRs in Figure 3 .
For the HBCD TM and the three individual diastereoisomers, common structural features are obvious and are well reflected by a high correspondence in toxicity profiles ( Figs: 3 and 4) . Apparently, the toxicity profile of mono-orthobrominated BDE-28 resembles the HBCD profile better than the [2,2#]-substituted PBDEs profile (cluster II), probably due to the lower potency of BDE-28 in the various bioassays than the PBDEs from cluster II. Cluster I contains compounds with toxicity profiles that deviate most from all other BFRs, i.e., moderate to very high potency in the TTR and E2SULT assay (Fig. 3) . It contains the two hydroxylated BFRs, TBBPA and 246-TBP, as well as the TBBPA-DBPE TM, which may contain considerable amounts of its phenolic precursor TBBPA. On the other hand, 6OH-BDE-47 is the only hydroxylated compound from the test set that is not clustered in cluster I, probably because its toxic potency was not as restricted to the TTR and E2SULT assays as it was for the BFRs from cluster I. It cannot be excluded, however, that the moderate to high AR-, PR-, and ER-antagonistic potencies of 6OH-BDE-47 are caused by cytotoxicity rather than competition for receptor binding and should therefore be classified as 1 in Figure 3 . In that case, the toxicity profile of 6OH-BDE-47 resembles that of the BFRs in cluster I.
Resemblance in structure-activity relationships can also explain the strong correlations between different endpoints. For instance, the correlation between ER-agonistic, ARantagonistic, and PR-antagonistic potencies (Fig. 4) can be explained by high bioassay responses of BDE-19 and BDE-100, complying with the structural requirements for ERactivation (i.e., low bromination with a [2,2#6] or a [2,2#,4] substitution and no bromine substitutions adjacent to each other), AR inactivation (low bromination with ortho or orthopara substitution), and PR inactivation (tri-or tetra-ortho substitution) (this study; Harju et al., in press). As pointed out above, the strong correlation between TTR binding and E2SULT inhibition can be attributed to TBBPA and 246-TBP, which comply with the similar structure-activity requirements for these endpoints, i.e., an OH-group with one and preferably two adjacent bromine substituents.
Possible Implications for Human and Environmental Health
The finding that most BFRs tested in this study have considerable antiandrogenic potency is intriguing. The antiandrogenic potency of the environmentally relevant BDE-100 was 13 times higher than that of the well-known antiandrogenic drug flutamide. The presence of antiandrogenic compounds, like BFRs in the aquatic environment might present a plausible alternative explanation for the observed alterations in fish reproductive functions, which have so far been associated with the presence of (xeno-)estrogens in the aquatic environment (e.g., Sumpter, 2005) . Exposure of fish to antiandrogens has been associated with gonadal changes (induction of intersex), reduced spermatogenesis, demasculinization, and reduced sperm counts (Bayley et al., 2003; Kiparissis et al., 2003) . Similar changes in testicular function and sperm production have been observed in rodents exposed to antiandrogens (Kubota et al., 2003; Mahood et al., 2005; Uzumcu et al., 2004) including the penta-PBDE mixture DE-71 (Stoker et al., 2005) . Further studies aim at the elucidation of the relevance of antiandrogenicity by man-made chemicals including BFRs for changes in reproductive functioning in fish. In the same context, the antiprogestagenic properties of a wide set of BFRs should be considered with concern, as Sumpter (2005) recently stressed the extreme importance of some progesterones to fish, in which they act as pheromones crucial for eliciting physiological and behavioral responses in the other sex.
The in vitro potency of BFRs to interfere with T3-mediated effects also deserves follow-up investigation, especially since the T3-potentiating effect of HBCD alpha and the T3-antagonistic effect of BDE-206 were confirmed in additional T3-dependent in vivo assays with amphibian larvae (Schriks et al., in press ). The possibility that these compounds can affect T3-regulated processes in animal development is especially relevant because of their environmental relevance given the bioaccumulating potency of HBCD alpha (Zegers et al., 2005) and the presence of BDE-206 in sediments at relatively high concentrations (LaGuardia et al., 2004) .
For hydroxylated BFRs, the in vivo consequences of high in vitro TTR-binding and E2SULT-inhibiting potency for possible hypothyroidal and estrogenic effects deserves further attention. This holds not only for hydroxylated parent compounds such as TBBPA and 246-TBP but also for hydroxylated metabolites of PBDEs formed by microsomal biotransformation, which have much higher TTR-binding and E2SULT-inhibiting potency than the parent PBDE congener (Hamers et al., in press; Meerts et al., 2000) . In addition, direct toxicity of PBDEs also seems to be increased by hydroxylation. Additional experiments confirm that PBDE cytotoxicity to DR-and ER-CALUX cells increases after metabolization, especially for lower-brominated BFRs (Hamers et al., in press ).
Based on these new insights, implications for human and environmental health are expected for BFRs grouped in clusters I (TTR-binding and E2SULT inhibition), II (antiandrogenicity and antiprogestagenicity), and III (as II with T3 potentiation). For a more elaborate hazard assessment, we therefore suggest to test the in vivo ED potency of TBBPA, BDE-100, and HBCD, which are representative BFRs for clusters I, II, and III, respectively, with high environmental relevance. Special attention should be given to hypothyroidal and estrogenic effects of TBBPA, to estrogenic, antiandrogenic, antiprogestagenic, and hyperthyroidal effects of BDE-100, and to antiandrogenic, antiprogestagenic, and hyperthyroidal effects of HBCD.
CONCLUDING REMARKS
The systematic screening demonstrated in vitro ED potencies for a wider set of BFRs and for more modes of action than was ever tested before. Antiandrogenic, antiprogestagenic, (anti-)estrogenic, (anti-)dioxin-like, and T3-antagonistic potencies of BFRs were demonstrated at the receptor level. In addition, ED potencies of BFRs were revealed that are not directly linked to receptor (in-)activation, namely proteinbinding (TTR), enzyme inhibition (E2SULT), and potentiation of T3-mediated effects. For some BFRs, the ED potency was higher than for natural ligands or clinical drugs used as positive controls, viz, AR antagonism by di-ortho-[2,2#]-substituted PBDEs with no bromine substitutions adjacent to each other, and T4-TTR competition and E2SULT inhibition by hydroxylated BFRs. Based on similarity in ED profiles, BFRs could be classified into five different clusters. TBBPA, BDE-100, and HBCD were identified as the most environmentally relevant BFRs representing different toxicity profiles. These findings support further investigation of the potential ED effects of these BFRs in man and wildlife.
